September 22, 2026 · Phase 2 readout
BEIGF Phase 2 readout: a neutral outcome, +0.0%
On September 22, 2026, Sonrotoclax — BeOne Medicines Ltd. (Waldenstrom Macroglobulinemia) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved +0.0% in the window around the event.
The move
$21.95
1d before
$21.95
Event day
$21.95
1d after
$21.95
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.0% expected); the stock actually moved +0.0%. Model confidence at the time: 35%.
See the full scored track recordPre-catalyst setup
+0.0%
30-day run-up
0%
30-day volatility